Clinical trial
Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)
NCT06336330 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- April 25, 2024
- Completion date
- December 31, 2026
- Enrollment
- 831 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.